Medical research on long-term recovery from the Andes hantavirus

Researchers in Chile have documented persistent symptoms in patients recovering from the Andes hantavirus, lasting three to six months after initial infection. This study gained prominence following recent cases linked to the cruise ship MV Hondius. The Andes strain, primarily found in South America, is challenging to manage as the incubation period can reach eight weeks, and there are currently no specific vaccines or antiviral medications. If the infection develops into Hantavirus Cardiopulmonary Syndrome (HCPS), it causes severe respiratory and cardiovascular stress. Due to the high mortality rate of HCPS, early intensive care is essential for patient survival. The World Health Organization clarifies that the virus is well-understood by the medical community and does not pose a threat of becoming a COVID-19-style pandemic. Public health focus has expanded to monitor the post-acute phase of the disease, inspired by lessons learned from the COVID-19 pandemic.